Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study

Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study

Abstract Aim Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN‐induced p...

Full description

Saved in:
Bibliographic Details
Main Authors: Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Cancer Medicine
Subjects:
alkaline phosphatase
hepatocellular carcinoma
lenvatinib
monocyte
γ‐Glutamyl transpeptidase
Online Access:https://doi.org/10.1002/cam4.70065
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70065

Similar Items